3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Withdrawn
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Tongue Neoplasms
1
Photosensitivity Disorders
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Keratosis, Actinic
1
Gallbladder Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Bile Duct Neoplasms
1
Interventions
Carboplatin
18
Radiotherapy
10
Cisplatin
10
Pemetrexed
8
Paclitaxel
8
durvalumab
6
Magnetic Resonance Spectroscopy
6
Gemcitabine
6
Radiosurgery
5
Nivolumab
5
Etoposide
5
pembrolizumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiation
4
Erlotinib Hydrochloride
4
Docetaxel
4
Taxes
3
Standard of Care
3
Specimen Handling
3
Platinum
3
Cetuximab
3
Bronchoscopy
3
Biopsy
3
Bevacizumab
3
1,2-diaminocyclohexaneplatinum II citrate
3
sapanisertib
2
etoposide phosphate
2
capmatinib
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lung Neoplasms
×
Photochemotherapy
×
Clear all
NCT03346304
2019-02-01
PEARL
University College, London
Phase 2/3
Withdrawn